COMPANY PROFILE

NovaGo Therapeutics

Explore full profile

Human antibody therapeutics targeting cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration

Schlieren, SwitzerlandFounded 2015Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About NovaGo Therapeutics

NovaGo Therapeutics is a Schlieren, Switzerland clinical-stage biotech developing anti-Nogo-A biologics to promote nerve regeneration and functional recovery after central-nervous-system injury and disease, including acute spinal cord injury, stroke and secondary progressive multiple sclerosis. Founded on research identifying Nogo-A as a key inhibitor of neuronal regeneration, its lead candidate NG004 is a fully human therapeutic antibody designed to enable nerve-fiber outgrowth and neuroplasticity where approved regenerative options are lacking. In August/September 2026 NovaGo closed a CHF 24 million (USD 30 million) Series B co-led by Neurimmune and Pureos, with existing and new investors, complemented by non-dilutive support from the Swiss Paraplegic Foundation and Wings for Life, to run a 120-patient randomised double-blind proof-of-concept trial in acute spinal cord injury across Germany, Spain and Switzerland after encouraging Phase 1 results. Sources: PR Newswire / NovaGo 2 Sep 2026; Neurimmune; Wyss Zurich.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Schlieren, Switzerland
Employees: 10
Open positions: None listed
Dealroom signal: 74.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based, Swiss DT Biotech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Sep 2026	$30M	$120M	Wings for Life · Neurimmune Holding · Swiss InsurEvolution Partners Holding · Pureos Bioventures	↗
SERIES A✓Equity / VC	Mar 2019	$9.7M	$39M	Neurimmune Holding · Pureos Bioventures	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

NovaGo Therapeutics website traffic

Latest recorded traffic for NovaGo Therapeutics is 720 monthly website visits, down 26.5% over the last three months. NovaGo Therapeutics's team grew 0% over the past year.

Latest monthly visits720 3-month web change-26.5% 1-year team growth0%

Monthly website visitsMar 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAzureCell TherapiesRegenerative cell therapies for neurodegenerative disorders	Geneva, Switzerland	Operational	4	—	—
STSynendos TherapeuticsDeveloped first-in-class endocannabinoid modulators to restore natural functioning of the brain in CNS disorders	Basel, Switzerland	Operational
GLGliapharmA biotechnology company that develops treatments for neurological and psychiatric disorders	Geneva, Switzerland	Operational
PPPolyneuron PharmaceuticalsAccurate treatment of autoimmune disorders	Basel, Switzerland	Operational
ASAsceneuronDevelops effective therapeutics for orphan tauopathies	Lausanne, Switzerland	Operational
THTherachonDevelops treatments for serious genetic diseases	Basel, Switzerland	Closed
AAAdvanced Accelerator ApplicationsDevelops diagnostic and therapeutic products in the field of molecular nuclear medicine	Saint-Genis-Pouilly, France	Acquired
ANAleva NeurotherapeuticsPioneered directional deep brain stimulation DBS in Neuromodulation treatment of Parkinson's disease and essential tremor	Lausanne, Switzerland	Operational